ABITREXATE

Pre-Launch

methotrexate sodium

ANDAINJECTIONINJECTABLE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

ABITREXATE (methotrexate sodium) by Pfizer is reductase. Approved for refractory non-hodgkin lymphoma, part of a combination chemotherapy regimen, refractory non-hodgkin lymphomas and 6 more indications.

Drug data last refreshed 1mo ago

Mechanism of Action

reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively…

Indications (7)

refractory non-Hodgkin lymphoma part of a combination chemotherapy regimen

Worked on ABITREXATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.